ÂÜÀòÂÒÂ×

Matthew Kraman is an accomplished professional in the field of immunology and drug discovery, currently serving as the Associate Director of Immunology and previously as Principal Scientist at Alchemab Therapeutics Ltd since September 2020. Prior to this role, Matthew acted as an Independent Consultant specializing in drug discovery, particularly in immuno-oncology and preclinical research, between May and September 2020. From September 2018 to May 2020, Matthew was the Director of Business Development at Simcere Pharmaceutical Group (Europe), focusing on the identification of emerging technologies in immunology and oncology. Matthew's earlier experience includes serving as Principal Scientist at F-star Biotechnology Ltd. from August 2013 to August 2018, where leadership was provided for the clinical development of FS118 (LAG-3/PD-L1) bispecific. Matthew began their research career as a Senior Postdoctoral Fellow at the University of Cambridge and holds a PhD in Immunology from the same institution.